0001104659-21-128203.txt : 20211020 0001104659-21-128203.hdr.sgml : 20211020 20211020210755 ACCESSION NUMBER: 0001104659-21-128203 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211019 FILED AS OF DATE: 20211020 DATE AS OF CHANGE: 20211020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dayno Jeffrey M. CENTRAL INDEX KEY: 0001615993 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 211335434 MAIL ADDRESS: STREET 1: 460 EAST SWEDESFORD ROAD STREET 2: SUITE 1050 CITY: WAYNE STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 tm2129561-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-10-19 0 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001615993 Dayno Jeffrey M. 630 W. GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462 0 1 0 0 Chief Medical Officer Common Stock 2021-10-19 4 M 0 14099 8.22 A 14099 D Common Stock 2021-10-19 4 S 0 14099 43.1262 D 0 D Common Stock 2021-10-19 4 M 0 4101 8.22 A 4101 D Common Stock 2021-10-19 4 S 0 4101 43.7714 D 0 D Stock Option 8.22 2021-10-19 4 M 0 14099 0 D 2027-11-13 Common Stock 14099 57570 D Stock Option 8.22 2021-10-19 4 M 0 4101 0 D 2027-11-13 Common Stock 4101 53469 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.65 to $43.63. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.99. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. /s/ Christian Ulrich, Attorney-in-fact 2021-10-20